Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14315095 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL4427286 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL7136308 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL10064192 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL14067410 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL17672623 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL5803382 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL1438742 | 0.82 | SMN1; SMN2 (0.71) | SMN1; SMN2GAAALDH1A1KDM4ELMNA | |
| SCHEMBL3794817 | 0.81 | SLC18A3 (0.47) | SMN1; SMN2ALDH1A1KDM4ELMNAL3MBTL1 | |
| SCHEMBL3966761 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2GAAALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819328-A | Memantine urea derivative, preparation method thereof and application thereof in preparing medicine for treating soluble epoxide hydrolase mediated diseases | 沈阳药科大学 | 2023-03-21 | — | — | CN | claimed |
| EP-0213337-B1 | 4-CYANOPIPERIDINE DERIVATIVES, PREPARATION AND USE THEREOF | Eisai Co., Ltd. (JP) | 1991-05-15 | — | — | EP | claimed |
| JP-5286934-A | — | — | None | — | — | JP | disclosed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-117202923-A | Methods and compositions for modulating FGF activity | 康复治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | VTV THERAPEUTICS LLC | 2023-03-23 | — | — | US | disclosed |
| US-5066812-A | Chemical intermediates for bactericides | EISAI CO., LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| US-5006649-A | Bactericides | EISAI, CO. (JP) | 1991-04-09 | — | — | US | disclosed |
| US-4921850-A | GRAMNEGATIVE AND GRAMPOSITIVE BACTERICIDE | EISAI CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0264091-A2 | 3-Propenylcephem derivative, preparation thereof, chemical intermediates therein, pharmaceutical composition and use | Eisai Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4721788-A | 4-cyanopiperidine derivatives | EISAI CO., LTD. (JP) | 1988-01-26 | — | — | US | disclosed |
| US-4721788-A | 4-cyanopiperidine derivatives | EISAI CO., LTD. (JP) | 1988-01-26 | — | — | US | disclosed |
| EP-0213337-A1 | 4-cyanopiperidine derivatives, preparation and use thereof | Eisai Co., Ltd. (JP) | 1987-03-11 | — | — | EP | disclosed |
| EP-0213337-A1 | 4-cyanopiperidine derivatives, preparation and use thereof | Eisai Co., Ltd. (JP) | 1987-03-11 | — | — | EP | disclosed |
| US-4117140-A | BRONCHODILATING PIPERIDINOETHYL BENZOPYRANOPYRIDINONES | BROWN RICHARD E | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | SMN1; SMN2 2945/4885GAA 473/4885ALDH1A1 4800/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | SMN1; SMN2 3147/4885GAA 284/4885ALDH1A1 1697/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | SMN1; SMN2 3632/4885GAA 237/4885ALDH1A1 1872/4885 |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | SMN1; SMN2 4666/4885GAA 1684/4885ALDH1A1 3818/4885 |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | ALDH1A2, UACA, PDE6D | SMN1; SMN2 3936/4885GAA 997/4885ALDH1A1 124/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | SMN1; SMN2 7/4885GAA 95/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.